STRO
SUTRO BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$15.34
−0.90%Aug 12, 2026, 00:00 UTC
Sutro Biopharma reported Q2 2026 revenue of $9.8 million, down from $63.7 million in Q2 2025, with a net loss of $38.5 million and diluted EPS of -$2.33.
Jul 8, 2026, 00:00 UTC
Aura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.